N/A N=124 GORE® VIABAHN® Endoprosthesis Post-Marketing Surveillance Study
Vascular Stent-Graft Stenosis
Primary: Number of Subjects With Loss of Primary Patency of Target Lesion — 81 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=293 GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis
Renal Failure · Hemodialysis
Primary: Target Lesion Primary Patency at 6 Months — 52.9; 35.5 Percentage of Subjects
N/A N=275 FLUENCY® PLUS Endovascular Stent Graft for In-stent Restenosis
Restenosis
Primary: Percentage of Participants With Access Circuit Primary Patency (ACPP) That is Superior for FLUENCY® PLUS Endovascular Stent Graft (Following Percutaneous Transluminal…
Phase 4 N=148 GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study
Peripheral Vascular Diseases
Primary: Efficacy: Primary Patency at Three Years — 24.2; 25.9 percentage of subjects
N/A N=86 Wall Shear Stress and Neointimal Healing Following PCI in Angulated Coronary Vessels
Coronary Artery Disease
Primary: In Stent Mean Cross-sectional Area of Neo-intimal Tissue Coverage — 1.381; 0.949 mm^2
N/A N=158 Clinical Evaluation of a Vascular Venous Anastomotic Connector [InterGraft VIG-only Study]
End Stage Renal Disease
Primary: Cumulative Patency at 6 Months — 146 Participants — p=<0.001
N/A N=29 JetStream (JS) Atherectomy in Femoropopliteal In-Stent Restenotic Lesions
Restenosis · Peripheral Vascular Disease
Primary: Acute Procedural Success — 29 limbs
N/A N=321 GORE® VIABAHN® Endoprosthesis Post-Marketing Surveillance Study (JPS 16-03)
Peripheral Arterial Disease
Primary: Primary Assisted Patency — 0.920; 0.873 probability
N/A N=71 Evaluation of the 25 Centimeter (cm) GORE® VIABAHN® Endoprosthesis
Peripheral Vascular Diseases
Primary: Successful Completion of the Assigned Treatment — 76.7 percentage of subjects
N/A N=51 Impact of Grafts and Endografts for Abdominal Aneurysms on Arterial Stiffness.
Aortic Aneurysm, Abdominal
Primary: Aix@75 — 31.8; 32.5 percentage
N/A N=144 VasQ External Support for Arteriovenous Fistula
Arterio-Venous Fistula · ESRD · Steal Syndrome
Primary: Primary Patency of AVF — 88 Participants
N/A N=5 Safety and Performance of a Vascular Patch in Pediatric Patients Undergoing Bidirectional Cava-pulmonary Anastomosis
Heart Defects, Congenital
Primary: The Number of Patch Related Serious Adverse Events. — 0 Participants
N/A N=134 A Study of the Gore VIABAHN BX for Treatment of Occlusive Disease in the Iliac Arteries.
Peripheral Arterial Disease
Primary: Composite of Major Adverse Events (MAEs) — 2.3 percentage of subjects experiencing MAE — p=<0.001
N/A N=158 Progel Vascular Sealant
Aortic Valve Stenosis · Aneurysm of Ascending Aorta · Aortic Valve Disorder
Primary: Time to Achieve Hemostasis at the Aortic Anastomotic Suture Line From the Time Surgical Clamps Are Released to Cessation of Leakage at the Treated Anastomotic Site With…
N/A N=50 Pulmonary Artery Repair With Covered Stents
Pulmonary Stenosis · Pulmonary Regurgitation · Tetralogy of Fallot
Primary: Successful Repair of Conduit Disruption — 48 participants
N/A N=171 Multi-center Study for Stent Graft System for Peripheral Artery
Peripheral Arterial Disease
Primary: Primary Assisted Patency — 91 Participants — p=<0.0001
N/A N=267 Evaluation of the GORE TIGRIS Vascular Stent
Peripheral Arterial Disease
Primary: Primary Safety Endpoint - Number of Participants Free From Major Adverse Events at 30 Days — 187; 69 participants
N/A N=207 Study Comparing Synthetic Vascular Grafts in Patients With Peripheral Artery Disease (PAD) Who Require Artery Bypass.
Peripheral Arterial Occlusive Disease
Primary: Number of Participants With Primary Patency — 70; 89 Participants — p=<.0001
Phase 2 N=82 Covered CP Stents for the Prevention or Treatment of Aortic Wall Injury Associated With Coarctation of the Aorta
Aortic Coarctation
Primary: Study Participants With Grade 4 or 5 in Degree of Aortic Wall Injury (AWI) and/or Aortic Arch Obstruction Without Clinical Worsening — 55 participants
N/A N=162 Venous Stent for the Iliofemoral Vein Investigational Clinical Trial Using the DUO Venous Stent System
May-Thurner Syndrome · Deep Vein Thrombosis · Chronic Venous Insufficiency
Primary: Safety - Number of Participants Free From Major Adverse Events (MAEs) at 30 Days — 157 Participants
Phase 4 N=20 Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging
Peripheral Artery Disease · Vascular Disease · Critical Limb Ischemia
Primary: Change in Percent Wall Volume (PWV) — 12.3; 3.9 Percent Wall Volume — p=0.22
N/A N=141 Iliac Artery Treatment With The Invatec Scuba™ Cobalt Chromium Stent (INTENSE)
Peripheral Artery Disease
Primary: Composite of Major Adverse Events (MAE) Defined as the Occurrence of In-hospital Myocardial Infarction (MI) or Target Segment Revascularization, Target Limb Loss, or…
N/A N=356 Retrospective Post-Market Clinical Follow-Up Study of GORE-TEX® Vascular Grafts and GORE® PROPATEN® Vascular Graft in Peripheral Artery Disease, Aortic Aneurysms, and Dialysis Access
PAD - Peripheral Arterial Disease · AAA - Abdominal Aortic Aneurysm · End-Stage Renal Disease
Primary: PAD Cohort: Primary Safety Outcome: Device-related Seroma or Infection — 0 percentage of participants
Phase 3 N=100 To Evaluate the Safety and Efficacy for GORE TAG Thoracic Endoprosthesis in the Treatment of Thoracic Aortic Disease
Aneurysm, Dissecting · Aortic Aneurysm, Thoracic
Primary: Percentage of Participants With Technically Successful Implant — 99.0 percentage of participants
N/A N=19 34mm Cuff Study for Endovascular Repair of Abdominal Aortic Aneurysms
Abdominal Aortic Aneurysm
Primary: Number of Participants With Proximal Type I Endoleak at Each Timepoint — 1; 0; 0; 0 Participants
Phase 3 N=138 Evaluation of the GORE® ACUSEAL Vascular Graft for Hemodialysis Access
End Stage Renal Disease
Primary: Cumulative Patency at 6 Months — 83.6 percentage of participants
N/A N=50 The Complete® Self-Expanding Stent and Stent Delivery System Registry
Peripheral Vascular Disease
Primary: The Number of Participants With Major Adverse Events (MAE) — 0 participants
N/A N=57 Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project
Atherosclerosis of Native Arteries of the Extremities
Primary: Primary Patency — 94.4 percentage of lesions
N/A N=119 GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER)
Peripheral Vascular Diseases
Primary: Primary Patency at 12 Months — 72.9 percentage of subjects
N/A N=200 ABRE Clinical Study of the Abre Venous Self-expanding Stent System
Iliofemoral Venous Obstruction
Primary: Primary Patency — 162 Participants — p=<0.0001